APMAdvances in Precision Medicine2424-85922424-9106Bio-Byword Scientific Publishing Pty. Ltd.10.26689/APM.v11i8.16101ArticleInflammatory Cytokines and Psoriasis: A Mendelian Randomization Studyhttps://artdesignp.com/journal/APM/11/8/10.26689/APM.v11i8.16101LiLu,YangSixuan,WangXiyan,ZhangLei,YangLi,TianJun20261182026-08-26Psoriasis, a chronic inflammatory skin disorder, has been posited to be influenced by circulating inflammatory cytokines. However, the causative link remains nebulous. The use of Mendelian Randomization (MR) analysis is gaining popularity in testing the causal impact of exposures on disease outcomes by utilizing data obtained from genome-wide association studies. Using a two-sample Mendelian randomization analysis model, we evaluated the causal relationship between 26 circulating inflammatory cytokines and psoriasis risk based on GWAS meta-analysis summary data. We identified significant causal associations between specific inflammatory cytokines and psoriasis. IL-14 and CTACK were associated with increased risk, while IL-1 receptor antagonist (IL-1ra) and MCP1 showed associations with reduced risk. Notably, IL-14 and CTACK emerged as potential risk factors, while IL-1ra and MCP1 appear to serve as protective factors. No significant effects were observed for IL-2ra, IL-2, IL-6, IL-17, IL-8, IL-10, IL-16, IL-18, MIF, MIG, MIP1a, MIP1b, RANTES, and CXCL9 on psoriasis. The research offers genetic epidemiology evidence that associates psoriasis risk with specific circulating inflammatory cytokines. These findings underscore the potential of cytokine-targeted therapies and the importance of cytokine profiling in clinical practice.Psoriasis, Mendelian randomization, Inflammatory cytokines, GWAS meta-analysis

[1] Boehncke WH, Schön MP, 2015, Psoriasis. Lancet (London, England), 386(9997): 983–994. [2] Rendon A, Schäkel K, 2019, Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences, 20(6): 1475. [3] Grän F, Kerstan A, Serfling E, et al., 2020, Current Developments in the Immunology of Psoriasis. The Yale Journal of Biology and Medicine, 93(1): 97–110. [4] Raharja A, Mahil SK, Barker JN, 2021, Psoriasis: A Brief Overview. Clinical Medicine (London, England), 21(3): 170–173. [5] Singh R, Koppu S, Perche PO, et al., 2021, The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. International Journal of Molecular Sciences, 22(23): 12793. [6] Conti P, Pregliasco F, Bellomo RG, et al., 2021, Mast Cells Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-inflammatory Cytokines IL-37, IL-38 and IL-1Ra. International Journal of Molecular Sciences, 22(15): 8076. [7] Karakawa M, Komine M, Hanakawa Y, et al., 2014, CCL27 Is Downregulated by Interferon Gamma via Epidermal Growth Factor Receptor in Normal Human Epidermal Keratinocytes. Journal of Cellular Physiology, 229(12): 1935–1945. [8] Bowden J, Holmes MV, 2019, Meta-analysis and Mendelian Randomization: A Review. Research Synthesis Methods, 10(4): 486–496. [9] Sekula P, Del Greco MF, Pattaro C, et al., 2016, Mendelian Randomization as an Approach to Assess Causality Using Observational Data. Journal of the American Society of Nephrology: JASN, 27(11): 3253–3265. [10] Frost B, Schmidt M, Klein B, et al., 2023, Single-cell Transcriptomics Reveals Prominent Expression of IL-14, IL-18, and IL-32 in Psoriasis. European Journal of Immunology, e2250354. [11] Qiao J, Jia QN, Jin HZ, 2019, Lack of Association of the IL-1RN and IL-10 Polymorphisms with Risk of Psoriasis: A Meta-analysis. Molecular Genetics & Genomic Medicine, 7(1): e00512. [12] Saggini A, Chimenti S, Chiricozzi A, 2014, IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants. Journal of Immunology Research, 2014: 964069. [13] Qiao Z, Zhao W, Liu Y, et al., 2023, Low-dose Interleukin-2 for Psoriasis Therapy Based on the Regulation of Th17/Treg Cell Balance in Peripheral Blood. Inflammation, 46(6): 2359–2373. [14] Ghoreschi K, Balato A, Enerbäck C, et al., 2021, Therapeutics Targeting the IL-23 and IL-17 Pathway in Psoriasis. Lancet, 397(10275): 754–766. [15] Karakawa M, Kishimoto M, Ohtsuki M, et al., 2021, Calcipotriol Induces the Production of CTACK/CCL27, One of the Potential Suppressive Factors in Psoriasis Inflammation. Journal of Dermatology, 48(12): 1949–1950. [16] Kutwin M, Woniacka A, 2023, Interleukins 20 and 8 – Less Widely Known Cytokines in Psoriasis. PostÄ™py Dermatologii i Alergologii, 40(2): 10. [17] Dorota PB, Aneta SD, Monika Z, et al., 2016, Assessment of Interleukin 16 Serum Levels and Skin Expression in Psoriasis Patients in Correlation with Clinical Severity of the Disease. PLOS ONE, 11(10): e0165577.